. 2019 Jun 9;10(16):3717–3727. doi: 10.7150/jca.32205

Table 2.

Comparisons showing improvement (>0 months) in overall survival and no improvement (≤0 months) in progression-free survival (n=25)

Reference	Disease site	Line of therapy	Treatment comparison	N	Median OS (months)	Median PFS (months)	Study Quality
Allen et al. 2014⁵⁴	SCLC	2	topotecan + ziv-aflibercept	55	4.6	1.4	8
Allen et al. 2014⁵⁴	SCLC	2	topotecan	51	4.2	1.4	8
Belani et al. 2016⁵⁵	SCLC	1	cisplatin + etoposide + vismodegib	52	9.8	4.4	6
Belani et al. 2016⁵⁵	SCLC	1	cisplatin + etoposide	48	8.8	4.4	6
Bokemeyer et al. 2009⁵⁶	Colorectal	1	FOLFOX4 + cetuximab	170	18.3	7.2	7
Bokemeyer et al. 2009⁵⁶	Colorectal	1	FOLFOX4	168	18.0	7.2	7
Borghaei et al. 2015⁵⁷	NSCLC	2	nivolumab	292	12.2	2.3	6
Borghaei et al. 2015⁵⁷	NSCLC	2	docetaxel	290	9.4	4.2	6
Buikhuisen et al. 2016⁵⁸	Mesothelioma	1	axitinib	14	18.9	5.8	4
Buikhuisen et al. 2016⁵⁸	Mesothelioma	1	no treatment	11	18.5	8.3	4
Govindan et al. 2017⁵⁹, ⁶⁰	NSCLC	1	chemotherapy + ipilimumab	479	10.9*	5.6	8
Govindan et al. 2017⁵⁹, ⁶⁰	NSCLC	1	chemotherapy + placebo	477	10.7*	5.6	8
Han et al. 2017⁶¹	NSCLC	1	gefitinib	41	25.8	5.7	7
Han et al. 2017⁶¹	NSCLC	1	pemetrexed + carboplatin	40	24.3	11.9	7
Herbst et al. 2016⁶²	NSCLC	2+	pembrolizumab 2 mg/kg	345	10.4	3.9	7
Herbst et al. 2016⁶²	NSCLC	2+	docetaxel	343	8.5	4.0	7
Herbst et al. 2016⁶²	NSCLC	2+	pembrolizumab 10 mg/kg	346	12.7	4.0	7
Herbst et al. 2016⁶²	NSCLC	2+	docetaxel	343	8.5	4.0	7
Jonasch et al. 2017⁶³	Renal cell	2+	MK-2206	29	23.5	3.7	5
Jonasch et al. 2017⁶³	Renal cell	2+	everolimus	14	15.7	6.0	5
Kawaguchi et al. 2014¹⁶	NSCLC	2+	erlotinib	150	14.8	2.0	7
Kawaguchi et al. 2014¹⁶	NSCLC	2+	docetaxel	151	12.2	3.2	7
Lee et al. 2013⁶⁴	NSCLC	2	erlotinib	82	22.8	3.8	7
Lee et al. 2013⁶⁴	NSCLC	2	pemetrexed	80	17.7	4.4	7
Lee et al. 2014⁶⁵	NSCLC	2+	erlotinib	40	3.4	1.6	9
Lee et al. 2014⁶⁵	NSCLC	2+	placebo	40	2.9	1.6	9
NCT00069095 ⁶⁶	Colorectal	1	(FOLFOX4 or XELOX) + bevacizumab	699	18.9	8.0	7
NCT00069095 ⁶⁶	Colorectal	1	(FOLFOX4 or XELOX) + placebo	701	18.1	9.4	7
NCT00448279 ⁶⁷	Breast	2	chemotherapy + trastuzumab	29	26.7	9.4	4
NCT00448279 ⁶⁷	Breast	2	chemotherapy	29	19.1	9.7	4
NCT00597116 ⁶⁸	Mesothelioma	2	vandetanib	14	7.8	1.8	3
NCT00597116 ⁶⁸	Mesothelioma	2	vinorelbine	11	6.4	3.8	3
NCT00887159 ⁶⁹	SCLC	1	cisplatin + etoposide + vismodegib	56	9.8	4.4	5
NCT00887159 ⁶⁹	SCLC	1	cisplatin + etoposide	56	8.8	4.4	5
NCT01585987 ⁷⁰	Gastric	2	ipilimumab	57	12.7	2.7	5
NCT01585987 ⁷⁰	Gastric	2	best supportive care	57	12.1	4.9	5
Pirker et al. 2009⁷¹	NSCLC	1	cetuximab + cisplatin + vinorelbine	557	11.3	4.8	7
Pirker et al. 2009⁷¹	NSCLC	1	cisplatin + vinorelbine	568	10.1	4.8	7
Powles et al. 2017⁷²	Bladder	Maintenance	lapatinib	116	12.6	4.5	9
Powles et al. 2017⁷²	Bladder	Maintenance	placebo	116	12.0	5.1	9
Propper et al. 2014⁷³	Pancreatic	2	erlotinib	104	4.0	1.4	9
Propper et al. 2014⁷³	Pancreatic	2	placebo	103	3.1	1.4	9
Sanborn et al. 2017¹³	SCLC	1	platinum + etoposide + vandetanib	34	13.2	5.6	8
Sanborn et al. 2017¹³	SCLC	1	platinum + etoposide + placebo	33	9.2	5.7	8
Scagliotti et al. 2010⁷⁴	NSCLC	1	carboplatin + paclitaxel + sorafenib	464	10.7	4.6	10
Scagliotti et al. 2010⁷⁴	NSCLC	1	carboplatin + paclitaxel + placebo	462	10.6	5.4	10
Vilgrain et al. 2017⁷⁵	Hepatocellular	1	sorafenib	222	9.9	3.7	8
Vilgrain et al. 2017⁷⁵	Hepatocellular	1	radiotherapy	237	8.0	4.1	8
Yoon et al. 2016⁷⁶	Esophagogastric	1	modified FOLFOX6 + ramucirumab	84	11.7	6.4	10
Yoon et al. 2016⁷⁶	Esophagogastric	1	modified FOLFOX6 + placebo	84	11.5	6.7	10

NSCLC=non-small cell lung cancer; SCLC=small cell lung cancer; FOLFOX=fluorouracil + oxaliplatin; XELOX= capecitabine + oxaliplatin

*Survival data for the full cohort were not published, these data are available in the clinicaltrials.gov record